Alpha-fetoprotein response in advanced hepatocellular carcinoma receiving cytostatic agent

Journal of Clinical Oncology

Volumn 27, Issue 36, 2009, Pages

  Chen, Li Tzong ^a,b,c   Shiah, Her Shyong ^a,b   Chao, Yee ^d   Chang, Jang Yang ^a,b   Cheng, Li Ting ^a   Whang Peng, Jacqueline ^a,e  

^a NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^b NATIONAL CHENG KUNG UNIVERSITY HOSPITAL   (Taiwan)

^c KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^d TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^e TAIPEI MEDICAL UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; DOXORUBICIN; THALIDOMIDE; TUMOR MARKER;

ACCURACY; ADVANCED CANCER; CANCER CHEMOTHERAPY; DRUG EFFICACY; HEPATITIS B VIRUS; HEPATOGRAPHY; HUMAN; LETTER; LIVER CELL CARCINOMA; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PATIENT SELECTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR VOLUME; BLOOD; LIVER TUMOR; METABOLISM; NOTE; RADIOGRAPHY;

ALPHA-FETOPROTEINS; CARCINOMA, HEPATOCELLULAR; HUMANS; LIVER NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 74949116128     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2009.23.8311     Document Type: Letter

References (3)

1. Chan SL, Mo FK, Johnson PJ, et al: New utility of an old marker: Serial alpha-fetoprotein measurement in predicting radiologic response and survival of patients with hepatocellular carcinoma undergoing systemic chemotherapy. J Clin Oncol 27:446-452, 2009
2. Chen LT, Liu TW, Chao Y, et al: Alpha-fetoprotein response predicts survival benefits of thalidomide for advanced hepatocellular carcinom. Aliment Pharmacol Ther 22:217-226, 2005
3. Liaw YF, Tai DI, Chen TJ, et al: Alpha-fetoprotein changes in the course of chronic hepatitis: Relation to bridging hepatic necrosis and hepatocellular carcinoma. Liver 6:133-137, 1986